AAIC 2021 Recap August 24, 2021 Signant Health Posted in Scientific Advisory Share: LinkedInTweet Here are a few takeaways from Signant’s presentations that you may have missed: Dr. Miller led a product showcase, Glimmers of Hope: Facilitating Breakthroughs in Dementia Clinical Trials, that demonstrated how Signant, the first company to implement electronic assessments in dementia clinical trials, applies rater training, data quality management, and eCOA to optimize endpoint reliability in these trials. Our clinical vice president, Dr. David Miller, presented the poster “Impact of Protocol Design on Between Scale Discrepancies in Early AD Clinical Trials.” Download the Poster Our analytics guru, Dr. Alan Kott, presented the poster “Exploring Discordant Data in Dementia Clinical Trials.”Download the Poster To learn more about why Signant is the global leader in dementia clinical research, and reach out to our in-house experts to discuss your dementia programs. Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics. Recent Posts Scientific Advisory 11 Perspectives on the Present and Future of Clinical Development Apr 13, 2023 Signant Health Learn more Clinical Supplies Consider Patients First in Direct-to-Patient Trial Designs Mar 31, 2023 James Stringer Learn more eCOA Clinical Viewpoints Episode 1 Recap – Optimizing Pediatric Trials to Generate High-Quality Data Feb 07, 2023 Signant Health Learn more eCOA Webinar Recap: Decentralized by Design-Optimizing Trials for Remote Conduct Feb 07, 2023 Signant Health Learn more eCOA Trial Optimization as the Focus for Decentralized Methods Dec 12, 2022 Signant Health Learn more
Here are a few takeaways from Signant’s presentations that you may have missed: Dr. Miller led a product showcase, Glimmers of Hope: Facilitating Breakthroughs in Dementia Clinical Trials, that demonstrated how Signant, the first company to implement electronic assessments in dementia clinical trials, applies rater training, data quality management, and eCOA to optimize endpoint reliability in these trials. Our clinical vice president, Dr. David Miller, presented the poster “Impact of Protocol Design on Between Scale Discrepancies in Early AD Clinical Trials.” Download the Poster Our analytics guru, Dr. Alan Kott, presented the poster “Exploring Discordant Data in Dementia Clinical Trials.”Download the Poster To learn more about why Signant is the global leader in dementia clinical research, and reach out to our in-house experts to discuss your dementia programs. Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.